During election cycles, much is made of policy positions on the economy, immigration, foreign affairs, etc. However, rarely is attention paid to the policy of science.
IV treatment is one of the most traditionalist and wide-spread treatments provided to the 90% of hospitalised patients, yet, recent supply challenges like the
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.